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Background: Clinical studies have demonstrated that intracoronary or intramyocardial transplantation
of bone marrow mononuclear cells (BMMNCs) into ischemic myocardium improves cardiac function.
The objective of the present study was to evaluate the safety and feasibility of intramyocardial BMMNC
transplantation into nongraftable areas in combination with off-pump coronary artery bypass grafting in
patients with ischemic cardiomyopathy. Methods: Five male patients with myocardial infarction lasting
for more than 1 month and with nongraftable myocardium received autologous mononuclear cell trans-
plantation during off-pump coronary artery bypass grafting. Autologous bone marrow was aspirated
from the iliac crest. BMMNCs (mean 1.6, standard error [SE] 0.3 × 109) including CD34-positive cells
(mean 6.8, SE 1.1 × 106) and AC133-positive cells (mean 3.1, SE 1.7 × 106) were injected into the
nongraftable ischemic myocardium. Heart function was evaluated with the use of echocardiography,
and myocardial perfusion was examined with single photon emission computed tomography tech-
netium-99mTc sestamibi scans. Results: Two months after cell transplantation, the mean ejection frac-
tion had increased by 7.4%, SE 1.9% (p = 0.016) compared with that before cell transplantation and off-
pump coronary artery bypass grafting. The increase in ejection fraction was not correlated with the
number of transplanted total mononuclear cells, CD34-positive cells and AC133-positive cells. Myocar-
dial perfusion at the cell-transplanted area increased after cell transplantation and off-pump coronary
artery bypass grafting. No arrhythmia was observed. Conclusion: The present clinical study suggests
that intramyocardial transplantation of autologous BMMNCs into the ischemic area during off-pump
coronary artery bypass grafting is both feasible and safe and has beneficial effects on cardiac function.
Contexte : Des études cliniques ont démontré que la transplantation intracoronarienne ou intramy-
ocardique de cellules mononucléaires de moelle osseuse (CMNMO) dans un myocarde ischémique
améliore la fonction cardiaque. L’étude visait à évaluer la sécurité et la faisabilité d’une transplantation
intramyocardique de CMNMO dans des régions non greffables combinée à un pontage aortocoronarien
hors circuit chez des patients atteints de myocardiopathie ischémique. Méthodes : Cinq patients vic-
times d’un infarctus du myocarde ayant duré plus d’un mois et dont le myocarde ne permettait pas une
greffe ont reçu une transplantation de cellules mononucléaires autologues au cours d’un pontage aorto-
coronarien pratiqué hors circuit. On a effectué une ponction de moelle osseuse autologue au niveau de
la crête iliaque. On a injecté des CMNMO (moyenne de 1,6, erreur type [ET] de 0,3 × 109), y compris
Interventional revascularizationand coronary artery bypass graft-
ing are standard treatment methods
for patients with ischemic cardiomy-
opathy. These approaches success-
fully relieve angina and improve
heart function in most patients 
with ischemic myocardium. How-
ever, complete revascularization is
not feasible in a large number of pa-
tients who have a nongraftable area
of ischemic myocardium due to dif-
fuse small vessel disease or multifocal
stenotic coronary artery. Without the
salvage of stunned or hibernating
myocardium, myocardial ischemia
rapidly results in necrosis and is fol-
lowed by heart failure. Patients with
end-stage heart failure can only be
treated by heart transplantation. Al-
though the outcome of heart trans-
plantation has been excellent, this
therapy is limited by the shortage of
donor organs and the side effects of
long-term immunosuppression.1,2
Cell transplantation has recently
received great attention as an alterna-
tive strategy in the treatment of pa-
tients with failing hearts. Several
studies using various animal models
have reported that fetal cardiomy-
ocytes,3 skeletal myoblasts,4 smooth
muscle cells,5 embryonic stem cells6
and bone marrow cells7–9 survive in
the infarcted myocardium after trans-
plantation and improve heart func-
tion. The use of autologous stem
cells eliminates both ethical concerns
inherent in using embryonic or fetal
cells and the clinical problem of im-
munorejection.10 In several clinical
studies, transplantation of autolo-
gous bone marrow cells11–15 and
skeletal myoblasts16,17 has been inves-
tigated for angiogenesis and myoge-
nesis in ischemic myocardium. These
studies demonstrated that stem cell
transplantation enhanced myocardial
perfusion and cardiac function in is-
chemic hearts of patients with acute
or chronic myocardial infarction.
In the present study, autologous
bone marrow mononuclear cells
(BMMNCs) were transplanted by in-
tramuscular injection into non-
graftable ischemic myocardium in 5
patients who were not suitable candi-
dates for complete revascularization.
Cell transplantation was performed
during off-pump coronary artery by-
pass grafting. We evaluated the clini-
cal safety and feasibility of a com-
bined therapy of bone marrow cell
transplantation and off-pump coro-
nary artery bypass grafting. We ex-
amined cardiac function and myocar-
dial perfusion of the ischemic hearts
2 months after treatment.
Methods
Patients
The protocol for the clinical study
conformed to the principles outlined
in the Declaration of Helsinki,18 and
the study was approved by the Ethical
Committee of the Yonsei University
College of Medicine. Written in-
formed consent was obtained from all
patients. Five patients were recruited
in this study (Table 1). All had a my-
ocardial infarction lasting for more
than 1 month as well as unstable
angina before admission. On electro-
cardiography (ECG), all patients
were found to have a myocardial in-
farction with pathological Q waves.
They did not have symptoms of con-
gestive heart failure. After admission,
the patients’ vessel disease, myocar-
dial infarction and cardiac function
were examined. The patients had
triple vessel coronary disease with dis-
tinct areas of akinesia or severe hy-
pokinesia at the left ventricular wall,
as identified by coronary angiography
and echocardiography. In all the pa-
tients, 3 coronary arteries had severe
stenosis and calcification, and thus it
was not easy to try internal interven-
tion such as coronary stent insertion
or balloon dilatation. Because these
patients had limited graftable areas in
the myocardium, coronary artery by-
pass grafting alone did not seem an
option to improve myocardial func-
tion significantly. These patients were
not candidates for complete revascu-
larization and had nongraftable but
viable ischemic myocardium. Prior to
operating, we determined graftable
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des cellules positives pour CD34 (moyenne de 6,8, ET de 1,1 × 106) et des cellules positives pour
AC133 (moyenne de 3,1, ET de 1,7 × 106) dans le myocarde ischémique où l’on ne pouvait pratiquer
de greffe. On a évalué la fonction cardiaque par échocardiographie et examiné une perfusion du my-
ocarde par imagerie de perfusion myocardique par tomographie d’émission monophonique au tech-
nétium-99mTc. Résultats : Deux mois après la transplantation de cellules, la fraction d’éjection
moyenne avait augmenté de 7,4 %, avec ET de 1,9 % (p = 0,016), comparativement à ce qu’elle était
avant la transplantation de cellules et le pontage aortocoronarien hors circuit. On n’a pas établi de lien
entre l’augmentation de la fraction d’éjection et le nombre de cellules mononucléaires, de cellules posi-
tives pour CD34 et de cellules positives pour AC133 transplantées au total. La perfusion du myocarde
dans la région de la transplantation de cellules a augmenté après celle-ci et le pontage aortocoronarien
hors circuit. On n’a pas observé d’arythmie. Conclusion : L’étude clinique en cours indique que la
transplantation intramyocardique de CMNMO autologues dans la région ischémique au cours d’un
pontage aortocoronarien hors circuit est à la fois faisable et sans danger et a des effets bénéfiques sur la
fonction cardiaque.
Table 1
General characteristics of patients
Pt Sex
Age,
y Angina MI
No. of
DCA
1 M 48 Unstable Inferior 3
2 M 73 Unstable Inferior 3
3 M 54 Unstable Inferior 3
4 M 63 Unstable Anterior 3
5 M 53 Unstable Anterior 3
DCA = diseased coronary arteries; M = male;
MI = location of myocardial infarction;
Pt = patient.
myocardium for coronary artery by-
pass grafting and viable regions in
nongraftable myocardium for cell
transplantation, using coronary an-
giography and magnetic resonance
imaging (MRI), respectively. In these
patients, improvement of myocardial
function was not expected to occur in
the nonbypassed region just by im-
provement of collateral blood flow.
We used echocardiography to evalu-
ate cardiac function. A single photon
emission computed tomography
(SPECT) technetium-99mTc ses-
tamibi (MIBI) scan was used to con-
firm the angiographic and echocar-
diographic data and to identify the
areas unsuitable for coronary artery
bypass grafting or interventional
revascularization as candidate regions
for cell transplantation. All surgeries
were performed under normal as op-
posed to emergency conditions, with-
out an intra-aortic balloon pump.
Cell preparation and identification
With the patients under general anes-
thesia, we aspirated 300–350 mL 
of bone marrow from the posterior
left iliac crest and collected it in a
tube containing heparinized buffered
saline. A COBE 2991 Cell Processor
(CaridianBCT) was used to isolate
BMMNCs and concentrate them in
a final volume of 10 mL. The total
time for cell processing was less than
1 hour. The BMMNCs were im-
munocytochemically stained for
CD34 and AC133 with the use of
FITC-labelled anti-CD34 antibodies
(BD Biosciences) and PE-labelled
anti-AC133 antibodies (Miltenyi
Biotech), respectively. The percent-
age of CD34- or AC133-positive
cells was analyzed by 2-colour 
flow cytometry (BD FACScan; BD 
Biosciences) and compared with an
immunoglobulin G isotype control.
Cell transplantation
During the isolation of mononuclear
cells, we performed off-pump coronary
artery bypass grafting on the patients,
using composite grafts with a left inter-
nal mammary artery or a radial artery.
We transplanted BMMNCs into my-
ocardium, excluding graftable regions
irrespective of myocardial infarction.
BMMNCs were injected into non-
graftable and infarcted regions in 3 pa-
tients (patients 1, 2 and 3). In non-
infarcted myocardium, there can be
nongraftable regions that are due to
severe calcification or multifocal steno-
sis, and BMMNCs were injected into
nongraftable and noninfarcted regions
in 2 patients (patients 4 and 5). After
coronary artery bypass grafting, 10 mL
of BMMNC suspension was injected
into 10–15 areas (0.7–1.0 mL per in-
jection) of nongraftable myocardium
with a 26-gauge needle. Finger pres-
sure was applied at the injection sites
to prevent cell leakage after cell trans-
plantation. Before cell injection,
patients received standard cardiac
surgery. After completion of the oper-
ation, patients were transferred to the
intensive care unit and monitored ac-
cording to standard procedures.
Safety assessment
We monitored all patients by contin-
uous ECG 2 days after their op-
eration. Until discharge, ECG and
auscultation were performed once
and 6 times daily, respectively, to de-
tect ventricular arrhythmia. At 2 and
4 months after coronary artery by-
pass grafting and BMMNC trans-
plantation, we monitored all patients
by ECG to detect any unfavourable
events such as ventricular arrhythmia,
inflammation and neoplasm. Imme-
diately after surgery and 24 hours af-
ter surgery, we measured creatine ki-
nase MB (CK-MB) in all patients.
Measurement of myocardial
perfusion and cardiac function
Two months after coronary artery
bypass grafting and cell transplanta-
tion, cardiac function of the patients
was evaluated with echocardiogra-
phy. One patient was followed with
MRI to examine myocardial wall
motion of the cell-injected region.
Between 2 and 4 months after treat-
ment, SPECT MIBI scanning was
performed to evaluate myocardial
perfusion. Data obtained were ana-
lyzed by hospital cardiologists.
Statistical analysis
Quantitative data were expressed as
mean and standard error (SE). We
compared cardiac ejection fraction
(EF) before and after cell transplan-
tation and coronary artery bypass
grafting, using the paired t test. We
used linear regression analysis to
evaluate the correlation between car-
diac function improvement and the
number of transplanted cells.
Results
Characterization of transplanted
BMMNCs
The total number of mononuclear
cells (Fig. 1) isolated from 300 to
350 mL of bone marrow was 1.6 (SE
0.3) × 109. Flow cytometric analysis
showed that the mononuclear cells
contained 6.8 (SE 1.1) × 106 CD34-
positive cells and 3.1 (SE 1.7) × 106
AC133-positive cells (Table 2).
General patient information
following cell transplantation
The patients received 1–2 bypass
grafts. After bypass grafting, we per-
formed multiple site injections of
BMMNCs (0.87–2.39 × 109; mean
1.6 [SE 0.3] × 109 cells/patient).
Because there was no obvious leak-
age from the cell injection sites, the
injected cells might be directed into
the nongraftable territories of my-
ocardium. There was no mortality
during or after surgery. Patients were
extubated within the first 12 hours
(range 4–12 h, mean 6 h) and moni-
tored in the intensive care unit for
2 days. There was no ventricular ar-
rhythmia or hemodynamic abnor-
mality recorded during this period
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(Table 3). Immediately and 24 hours
after surgery, no increase in the levels
of CK-MB activity was detected in all
patients. This result revealed that
there was no myocardial damage in
all patients during surgery. The me-
dian hospital time after coronary
artery bypass grafting and cell trans-
plantation was 9 (range 7–30) days.
An improvement in symptoms was
observed in all patients 2 months af-
ter coronary artery bypass grafting
and cell transplantation.
Cardiac function
Prior to coronary artery bypass graft-
ing and cell implantation, the mean
EF of the 5 patients as evaluated by
echocardiography was 45.8% (SE
2.4%) (Fig. 2). Two months after
coronary artery bypass grafting and
cell transplantation, the mean EF of
the 5 patients was 53.2% (SE 3.6%)
(Fig. 2). These results show that cell
transplantation and coronary artery
bypass grafting significantly im-
proved cardiac function (p = 0.016).
Correlations between the number
of total transplanted mononuclear
cells, CD34-positive cells and
AC133-positive cells and the differ-
ence in EF before and after treat-
ment were evaluated with linear re-
gression analysis. No significant
correlations were observed between
the difference in EF and the number
of total mononuclear cells, CD34-
positive cells or AC133-positive cells
(r = 0.412, 0.353 and 0.426, respec-
tively, Fig. 3A, B and C).
Myocardial perfusion
SPECT MIBI scans performed between
Yoo et al.
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Table 2
Location of grafting and transplantation and number of transplanted cells for
each patient
Patient Grafting*
Area of cell
transplant
Total cells
(×109)†
CD34+ cells
(×106)‡
AC133+ cells
(×106)§
1 LAD, OM1 Inf, Lat, A 2.39 6.24 —
2 LAD, D Inf, Lat, A 1.15 4.59 1.22
3 LAD, D Inf, Lat, A 1.67 10.75 8.29
4 LAD Inf, Lat, A 1.98 5.70 1.38
5 LAD, D Inf, Lat, A 0.87 6.55 1.51
A = apex; Ant = anterior wall; D = diagonal branch; Inf = inferior wall; LAD = left anterior descending artery;
Lat = lateral wall; OM1 = first obtuse marginal branch.
*Grafting = target vessels for coronary artery bypass grafting.
†Total cells = the number of total bone marrow mononuclear cells transplanted in each patient.
‡CD34+ cells = the number of CD34-positive cells present in transplanted cells.
AC133+ cells = the number of AC133-positive cells present in transplanted cells.
Table 3
Postoperative characteristics of
patients
Patient VA Angina
Myocardial
perfusion*
1 No No +++
2 No No ++
3 No No ++++
4 No No +++
5 No No ++
VA = ventricular arrhythmia.
*+/++/+++/++++ = degree of improved perfusion
with + as lack of myocardial perfusion and ++++
as good myocardial perfusion.
FIG. 1. Wright Giemsa staining of (A)
freshly isolated bone marrow cells and
(B and C) purified bone marrow
mononuclear cells before cell trans-
plantation.
p = 0.016
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FIG. 2. Ejection fraction of each patient before and 2 months after cell transplanta-
tion and coronary artery bypass surgery.
2 and 4 months after surgery showed
that myocardial perfusion at the in-
farcted region improved significantly
in all patients (Table 3 and Fig. 4).
None of the patients had ventricular
arrhythmia or malignant neoplasia,
and all patients were able to resume
normal daily activities.
Discussion
The present study demonstrates that
a combined therapy of off-pump
coronary artery bypass grafting and
intramuscular transplantation of au-
tologous BMMNCs for the treat-
ment of myocardial infarction is safe
and feasible and improves perfusion
and myocardial contractility. The
clinical status of all patients had im-
proved after 2–4 months follow-up
(Table 3). Examination with ECG
showed that left ventricular wall mo-
tion in the cell-transplanted area was
improved in all patients. Consistent
with improved regional wall motion,
EF increased significantly (p = 0.016)
after cell transplantation and off-
pump coronary artery bypass grafting
(Fig. 2).
The present phase I clinical study
focused on the safety and efficacy of
BMMNC transplantation combined
with off-pump coronary artery bypass
grafting for the treatment of myocar-
dial infarction. There were no com-
plications such as myocardial dam-
age, malignant neoplasia and cardiac
or systemic inflammation immedi-
ately or 2–4 months after cell trans-
plantation. In particular, ventricular
arrhythmia that would be fatal in pa-
tients receiving cell therapy was not
observed in any patient. All patients
resumed normal daily activity. Thus
the combined therapy might be safe
in clinical application. This result is
consistent with that of a previous
study indicating that intramyocardial
injection of autologous BMMNCs
did not increase the incidence of
ventricular arrhythmia and inflamma-
tion in humans.19 However, because
the follow-up period in the present
study was short, the safety of this
therapy must be further assessed in
longer-term studies with larger num-
bers of patients. Because transplanted
cells are exposed to perfusion imme-
diately after injection in cell trans-
plantation following off-pump coro-
nary artery bypass grafting, the
survival and engraftment of the
transplanted cells may be enhanced
in comparison with on-pump bypass
surgery. In hibernating areas, the un-
derlying physiological state allows for
restoration of myocardial function if
myocardial perfusion is improved.11
Therefore, we carefully selected pa-
tients who had viable myocardium
with akinesia or severe hypokinesia,
as evaluated by echocardiography
Bone marrow cell transplantation into ischemic myocardium
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FIG. 3. Correlation between the difference in ejection fraction before and after
treatment and the number of transplanted (A) total mononuclear cells, (B) CD34-
positive cells and (C) AC133-positive cells.
and MRI. Intramyocardial cell deliv-
ery was performed because these pa-
tients had had myocardial infarction
and unstable angina for more than
1 month, making it likely that hom-
ing signalling would be weak and
not optimal for cell engraftment.
The present study demonstrated
that a combined therapy of BMMNC
transplantation and off-pump coro-
nary artery bypass grafting improved
cardiac function and myocardial per-
fusion of infarcted heart. In the pre-
sent study, all patients were followed
by echocardiography to examine my-
ocardial wall motion. With echocar-
diography, it is difficult to distinguish
the wall motion of the cell-injected
region from global myocardial wall
motion. Therefore, one patient was
monitored with MRI, which is a
more accurate method of examining
regional myocardial wall motion.
With MRI, we observed mild im-
provement of myocardial wall motion
in cell-injected regions. However, we
did not observe a correlation between
the number of injected cells and im-
provement in EF (Fig. 3). This might
be owing to the small number of pa-
tients rather than to nonefficacy of
combined therapy. In addition,
SPECT MIBI scan results (Table 3)
showed that perfusion improvement
was the most significant in the patient
(patient 3) receiving the largest num-
ber of CD34- and AC133-positive
cells. SPECT MIBI scan results can
be influenced by adjacent area revas-
cularization, but the perfusion im-
provement in the regions with no
perfusion might be mainly due to cell
transplantation. This correlation
should be examined further in a fu-
ture study with a large number of pa-
tients.
Several clinical studies have re-
ported that implantation of skeletal
myoblasts16,17 or cells derived from
bone marrow11–15 into ischemic heart
induced myogenesis and angiogenesis
and thereby increased myocardial
perfusion and prevented ventricular
dilatation and heart failure. Menasche
and colleagues16,17 performed the first
clinical trial of autologous myoblast
transplantation into infarcted my-
ocardium in combination with coro-
nary artery bypass grafting. After cell
transplantation, there was evidence of
contraction and viability in the cell-
transplanted scar area. Although the
results are encouraging, transplanta-
tion of only myogenic cell types
might not induce efficient revascular-
ization of ischemic tissue. Stamm and
colleagues12 transplanted autologous
AC133-positive bone marrow cells
into the infarcted area of patients af-
ter myocardial infarction and re-
ported that bone marrow cell trans-
plantation is safe and of benefit to
cardiac function. The present study
revealed that autologous stem cell
therapy could be applied with coro-
nary artery bypass grafting to treat
myocardial infarction. The significant
finding of the present study is that in-
tramyocardial transplantation of au-
tologous BMMNCs during off-pump
coronary artery bypass grafting is
feasible and safe and has beneficial
effects on myocardial perfusion.
BMMNCs have been known to con-
tain various stem and progenitor
cells, including mesodermal progeni-
tor cells, hematopoietic progenitor
cells and endothelial progenitor
cells.13 CD34- and AC133-positive
cells in bone marrow are known as
endothelial progenitors capable of
differentiating into endothelial cells.20
In addition, BMMNCs secrete vari-
ous cytokines (i.e., vascular endothe-
lial growth factor, insulin-like growth
factor and platelet-derived growth
factor) that can stimulate regenera-
tion and proliferation in residual nor-
mal myocytes and endogenous car-
diac stem cells.15 To take advantage of
this large and heterogeneous regener-
ative potential, we decided to use all
the mononuclear cells isolated from
the bone marrow aspirate rather than
a subpopulation. The transplanted
cell number of the present study was
not significantly different from that of
a previous clinical study.12
The major limitations of the pre-
sent study are that the study design
and the small number of patients en-
rolled limit conclusions about the ef-
ficacy and safety of the combined
therapy. The type and number of
transplanted cells used for the treat-
ment of myocardial infarction
should be optimized to enhance
therapeutic efficacy in further stud-
ies. That said, after cell transplanta-
tion, the myocardial perfusion at the
cell-transplanted area, which was
Yoo et al.
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FIG. 4. Photographs of single photon emission computed tomography 
technetium-99mTc sestamibi scan of patient 3 before cardiac surgery and cell
transplantation (top panel) and after cardiac surgery and cell transplantation (bot-
tome panel). Preoperative ischemic regions are indicated by arrows, and postoper-
ative regions that received cell transplantation are indicated by arrowheads. Im-
provement in myocardial perfusion was observed in the ischemic region after
bypass surgery and cell transplantation.
previously nonperfused or severely
hypoperfused, was significantly im-
proved in all patients (Table 3 and
Fig. 4). Although coronary artery
bypass grafting can contribute to im-
provement in myocardial perfusion,
an increase in perfusion by collater-
als originating from the bypassed
areas after coronary artery bypass
grafting would not be expected to
cause functional recovery of areas
that are difficult to perfuse.16 Thus
the improved perfusion in the cell-
transplanted area in the present
study is assumed to be mainly due to
the engrafted BMMNCs. However,
the present study was not designed to
compare the therapeutic efficacy of
single treatment because this study
has no control groups (a BMMNC
transplantation–only group or an 
off-pump coronary artery bypass
grafting–only group). The effects of
concomitant coronary artery bypass
grafting should also be addressed in
further studies with control groups.
Conclusion
In summary, the present phase I clin-
ical study demonstrates that intra-
myocardial implantation of autolo-
gous BMMNCs following coronary
artery bypass grafting ameliorated
myocardial ischemia and improved
the cardiac function of ischemic
hearts. It was safe and feasible to
simultaneously perform coronary
artery bypass grafting and cell trans-
plantation in ischemic myocardium
of beating hearts. Further studies
with a large number of patients and
long-term follow-up are required to
evaluate the effectiveness of this
method.
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